- <![CDATA[Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)]]><![CDATA[Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.]]>onclive · 2mo ago↗ source
- <![CDATA[Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss]]><![CDATA[How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.]]>onclive · 2mo ago↗ source
- Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacyHere we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but slowed patients’ clinical decline…